Traws Pharma Balance Sheet Health
Financial Health criteria checks 1/6
Traws Pharma has a total shareholder equity of $-2.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $8.9M and $11.0M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$5.41m |
| Equity | -US$2.03m |
| Total liabilities | US$10.97m |
| Total assets | US$8.94m |
Recent financial health updates
Recent updates
We're Keeping An Eye On Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Rate
Mar 09
Here's Why We're Watching Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Situation
Apr 22Onconova Therapeutics (NASDAQ:ONTX) Is In A Good Position To Deliver On Growth Plans
Jul 27Will Onconova Therapeutics (NASDAQ:ONTX) Spend Its Cash Wisely?
Mar 21Companies Like Onconova Therapeutics (NASDAQ:ONTX) Are In A Position To Invest In Growth
Dec 06Onconova Therapeutics names Mark Gelder as chief medical officer
Jun 01Onconova Therapeutics announces $8.7M registered direct offering
Jan 07Onconova cleared to start Phase 1 trial for cancer therapy
Dec 24Onconova Therapeutics EPS in-line, misses on revenue
Nov 12Financial Position Analysis
Short Term Liabilities: TRAW has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: TRAW has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: TRAW is debt free.
Reducing Debt: TRAW's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TRAW has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: TRAW has less than a year of cash runway if free cash flow continues to grow at historical rates of 2.6% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/29 17:49 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Traws Pharma, Inc. is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Thomas Cooper | Edison Investment Research |
| Etzer Darout | Guggenheim Securities, LLC |
| Michael Schmidt | Guggenheim Securities, LLC |